Post by icemandios on Dec 11, 2018 13:12:16 GMT
PolarityTE Announces Former FDA Official and Johnson & Johnson Executive Minnie Baylor-Henry Joins Board of Directors
While at the FDA, Ms. Baylor-Henry served as Regulatory Review Officer, Director/Branch Chief-Division of Drug Marketing, Advertising and Communications and National Health Fraud Coordinator at the FDA Office of Regulatory Affairs. Ms. Baylor-Henry's career at Johnson & Johnson included senior roles as the Vice President of U.S. Regulatory Affairs and Medical Affairs for Specialty Pharmaceuticals, Vice President of U.S. Regulatory Affairs and Medical Affairs for OTC products and Worldwide Vice President of Regulatory Affairs for Medical Devices. Additionally, Ms. Baylor-Henry was the National Director for Regulatory, Risk and Compliance for the life science division at Deloitte. She currently operates her own consulting firm, providing strategic regulatory affairs advice to pharmaceutical, biopharmaceutical and medical device companies.
As a leader in the life sciences regulatory field, Ms. Baylor-Henry served as the Chair of the Board of Directors for the Food and Drug Law Institute and the Drug Information Association, two of the most well-known and highly regarded associations for professionals in the food and drug space. Ms. Baylor-Henry received her pharmacy degree from Howard University's College of Pharmacy and a law degree from Catholic University's Columbus School of Law.
Denver M. Lough, MD, PhD, Chairman and Chief Executive Officer of PolarityTE commented, "We are thrilled that Ms. Baylor-Henry has joined our Board, and we look forward to capitalizing on her experience and wisdom as we continue to grow our product portfolio. Minnie's depth and breadth of knowledge across a variety of products, regulatory pathways and markets will be invaluable as we continue to develop and market products based on our platform technology."
Ms. Baylor-Henry commented, "After learning about PolarityTE and its potential to change the practice of medicine with its innovative technology and products, I was enthusiastic to join the Board and to be able to contribute to the company's success. I look forward to supporting PolarityTE's mission to bring medical technology to patients and providers that is truly different and life-changing."
PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. The PolarityTE platform technology begins with a small piece of the patient's own, or autologous, healthy tissue, rather than artificially manipulated individual cells. From this small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to enhance and stimulate the patient's own cells to regenerate the target tissues. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures with the patient's own tissue and uses the patient's own body to support the regenerative process to create the same tissue from which it was derived. PolarityTE's innovative method is intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing. Learn more at www.PolarityTE.com – Welcome to the Shift®.
